Summary
- Immunome has filed proposed terms for a $30 million IPO.
- The firm is advancing antibody-based treatment candidates for cancer and the Covid-19 virus.
- IMNM is still at a preclinical stage of development, so the IPO is likely more suited to institutional investors.
- Looking for more investing ideas like this one? Get them exclusively at IPO Edge. Get started today »
Quick Take
Immunome (IMNM) has filed to raise $30 million in an IPO of its common stock, according to an S-1 registration statement.
The company is developing antibody therapies for cancer and infectious diseases.
IMNM is still at a preclinical stage of development for its programs, so the IPO is likely more suited to long-term hold institutional investors.
Company & Technology
Exton, Pennsylvania-based Immunome was founded to develop antibody therapeutics with a primary focus on cancer treatments and the more recent addition of developing antibodies for SARS-CoV-2, or Covid-19.
Management is headed by president and Chief Executive Officer Mr. Purnanand Sarma, Ph.D, who has been with the firm since June 2019 and was previously president and CEO of Taris Biomedical and VP and General Manager of World-wide Drug Delivery Technologies at Cephalon.
Below is a brief overview video of antibody-based therapies for cancer:
